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Response to Stanton-Hicks et al.
With great interest we read the landmark paper ‘Reflex sym­
pathetic dystrophy: changing concepts and taxonomy’ (Stanton- 
Hicks et al., 1995),
It is refreshing that finally the defective terminology RSD as 
well as its defective definition, has been re-evaluated. In our 
experience, the blockbustering around the sole role of the ortho- 
sympathic system has prohibited the development and propaga­
tion of new thoughts in this field. Papers from our department 
indicating an excessive inappropriate inflammatory response in 
generating this ailment, have been rejected up to three times by 
leading journals, because the diagnosis was not confirmed by 
sympathetic blocks. On the other hand, we started these studies 
because our pain-team refused to administer sympathetic blocks 
because of the poor results in the acute stage (Driessen et al.,
1983).
We fully agree with most of the propositions formulated in 
the new concept. We, however, would suggest not to include 
pain as ‘the sine qua non for diagnosis’ and not to require ‘an 
initiating noxious event’.
In a consecutive series of 829 patients (Veldman et alM 
1993), showing the complex symptomatology of RSD or CRPS, 
7% of the patients did not complain of (severe) pain, including 
pain as a prerequisite for CRPS might indicate an observer bias, 
as the authors of the above article all are actively involved in 
pain clinics. We therefore would suggest the terminology 
CRDS, complex regional dysfunction syndrome. The presenting 
(early) symptoms of CRDS as seen in a large trauma policlinic 
differ in this respect from the symptoms of a selected sub­
population seen in a pain clinic.
Furthermore» in our study CRDS did not occur after a previ­
ous noxious event in 10% of the patients. In these ‘spontaneous’ 
CRDS patients, symptomatology could not be differentiated 
from the post-noxious event CRDS patient.
Only opening up our mind will help solve the tremendous 
problems, caused by RSD, CRPS or CRDS, whatever the name.
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Primum noil nocere -  a paradoxical ally in defense of 
placebos in analgesic trials?
In the thirty five years since Bradford Hill (1963) posed the 
question, the ethics and use of placebos in clinical trials con­
tinue to be debated and divisive, in print (Turner et al., 1994; 
Rothman et al., 1994; Collier, 1995; Rothman, 1996), and at 
meetings (Public Policy Forum: 1997).
Protagonists and Regulatory Authorities claim that use of a 
placebo comparator is essential for robust scientific proof of 
efficacy, particularly when the assessment is entirely subjective 
as in the relief of pain, and that informed consent enables the 
patient to refuse enrollment in the study. For the case against 
placebo, antagonists insist that any new drug should be com­
pared with the established drug for the condition in question and 
in support cite the Nuremberg Code, the Declaration of Helsinki 
and denial of effective or best available therapy. This latter 
point is important because no one would wish knowingly to 
provide inadequate therapy to patients. Yet even therapy that is 
accepted as effective or best available leaves some patients in­
adequately treated and surely it is our responsibility as physi­
cians to have as few of these individuals as possible?
